ImmunoGen, Inc. - Common Stock (NQ:IMGN)

SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)

Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal ↗

December 12, 2023

Via Benzinga

AbbVie continues shopping spree with biotech buyout

December 12, 2023

While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend.

Via MarketBeat

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.

December 11, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Is AbbVie Stock a Buy Now? ↗

December 07, 2023

AbbVie's business could soon become more diversified.

Investors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately.

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 11, 2023

Via Benzinga

The 3 Best Cheap Stocks to Buy in December ↗

December 10, 2023

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

December 10, 2023

From ImmunoGen Inc.

AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? ↗

December 10, 2023

The big drugmaker went on a holiday shopping spree.

In investing, certain stocks catch the discerning eye of big players, drawing in substantial investments.

Market Movers: Why Big Players Are Investing Millions in These 3 Stocks ↗

December 08, 2023

Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.

AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next? ↗

December 08, 2023

TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93.

TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗

December 07, 2023

Via Investor's Business Daily

AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals ↗

December 07, 2023

Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the...

Via Benzinga

Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise ↗

December 06, 2023

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

Small Cap, Big Potential: 3 Russell 2000 Stocks to Watch ↗

December 06, 2023

The Russell 2000 index comprises small-cap companies, exposing investors to small organizations. Consider buying these Russell 2000 stocks.

FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer

December 05, 2023

From ImmunoGen, Inc.

IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN

December 04, 2023

From Kahn Swick & Foti, LLC

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)

December 04, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note ↗

December 04, 2023

AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $

Via Benzinga

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 01, 2023

From ImmunoGen, Inc.

Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review ↗

December 01, 2023

Software earnings were strong, while the Fed is shifting toward rate cuts.

Via Investor's Business Daily

Topics Economy Stocks

Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 01, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

ImmunoGen Stock Nearly Doubled On Thursday: What Happened? ↗

November 30, 2023

Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion.

Via Talk Markets

Why Abbvie Stock Popped Today ↗

November 30, 2023

The company announces a major deal worth over $10 billion.

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining around 300 points on Thursday. The Dow traded up 0.88% to 35,742.35 while the NASDAQ fell 0.79% to 14,145.17. The...

Nasdaq Falls Over 100 Points; Cracker Barrel Shares Slide After Q1 Results ↗

November 30, 2023

Via Benzinga

Topics Stocks

Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

November 30, 2023

Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak quarterly results.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 30, 2023

Via Benzinga

Crude Oil Falls Sharply; Kroger Posts Upbeat Earnings ↗

November 30, 2023

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded up 0.85% to 35,729.88 while the NASDAQ fell 0.71% to 14,156.60. The S&P...

Via Benzinga

Topics Stocks

ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal ↗

November 30, 2023

AbbVie Inc (NYSE: ABBV) has agreed to acquire ImmunoGen Inc (NASDAQ: IMGN) and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC)...

Via Benzinga

Why Is Soligenix (SNGX) Stock Up 285% Today? ↗

November 30, 2023

Soligenix stock is rising higher on Thursday with heavy trading of SNGX shares after getting FDA approval for a Phase 2 clinical trial.